MENU

Print This PageEmail this Page

News & Videos

Videos

Watch Video BBC Two Report on eTNS for PTSD

An in-depth report by the BBC about an ongoing trial of the Monarch eTNS device as a treatment for PTSD among veterans. Dr. Andrew Leuchter, Professor of Psychiatry at UCLA and Principal Investigator of the clinical trial is interviewed about his ongoing work with Trigeminal Nerve Stimulation.

Watch Video Patch for PTSD: Profiling a Veteran

WNDU in Indiana reports on the ongoing trial of the Monarch eTNS system, a collaboration between UCLA and the VA hospital, for veterans suffering from PTSD. The story profiles a veteran on the effects of trigeminal nerve stimulation treatment and discusses its prospects for more widespread clinical use.

Watch Video Veteran Benefits from eTNS for PTSD in Clinical Trial

KABC7 Eyewitness News in Los Angeles interviews Dr. Andrew Leuchter, lead investigator on a U.S. Army funded trial of eTNS for Veterans with Post-Traumatic Stress Disorder (PTSD), and profiles a veteran enrolled in the trial who benefited from the treatment.

Watch Video Presentation on eTNS at the 2014 Epilepsy Pipeline Conference

Dr. Christopher DeGiorgio gives an update on clinical studies of eTNS at the June 2014 Epilepsy Pipeline Conference sponsored by the Epilepsy Foundation and the Epilepsy Therapy Project.

Watch Video Study Finds Monarch eTNS System Helps ADHD

ABC7 in San Francisco reports on a study conducted at UCLA and presented at the American Psychiatric Association’s convention. The study found that nightly use of the eTNS resulted in significant improvement in ADHD symptom severity among children ages 7 - 14.

Watch Video February 2013 Royal Society of Medicine Innovations Summit

This video provides an overview of the science and clinical data behind eTNS. The footage was taken from a presentation given by Drs. Christopher DeGiorgio, and Colin Kealey at the 2013 Royal Society of Medicine Innovations Summit, held February 13th in London.

Watch Video UK Epilepsy Society interview

An interview conducted by the UK Epilepsy Society with Dr. Christopher DeGiorgio, inventor of eTNS, and Patrick Miller of NeuroSigma. This video shows how the eTNS device works and is a good reference for patients, family members and physicians interested in how eTNS could incorporate into their daily lives.

Watch Video eTNS Featured on CBS Los Angeles

The Monarch makes local news in this video featuring an interview with a patient who has used the eTNS device to successfully treat their epilepsy.


Press Releases

December 10, 2015
Preliminary Results Utilizing NeuroSigma's Monarch eTNS System for the Treatment of Traumatic Brain Injury Presented at the North American Neuromodulation Society Annual Meeting

NeuroSigma®, Inc. (NeuroSigma), today announced positive preliminary findings from a clinical study using non-invasive external Trigeminal Nerve Stimulation with the Monarch eTNS System® to treat combat veterans. Results were presented at the North American Neuromodulation Society (NANS) meeting in Las Vegas and mark the first report of using eTNS® in patients with Traumatic Brain Injury (TBI).

November 16, 2015
NeuroSigma's Monarch eTNS System Receives CE Mark Approval for ADHD

NeuroSigma®, Inc. (NeuroSigma) today announced that it has received CE Mark approval for its Monarch eTNS System® as treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and children age 7 and older. This CE Mark approval is the first for any non-drug treatment of ADHD in the European Union (EU).

May 4, 2015
NeuroSigma's Thin Film Nitinol Flow Diverting Stent Results Presented at the American Society of Neuroradiology Meeting

NeuroSigma®, Inc. (NeuroSigma), a California-based life sciences company, today announced that results of an animal study of its Thin Film Nitinol (TFN) flow diverter were presented on April 30th by Mayo Clinic researchers at the 53rd Annual Meeting of the American Society of Neuroradiology in Chicago, Illinois. A copy of the study abstract can be accessed via the conference website.

January 6, 2015
FDA Grants NeuroSigma Humanitarian Use Device (HUD) Designation

NeuroSigma®, Inc. (NeuroSigma) today announced that it has received a Humanitarian Use Device (HUD) designation from the Food and Drug Administration (FDA) for its eTNS neuromodulation therapy for the adjunctive treatment of the symptoms of Lennox-Gastaut Syndrome (LGS). The HUD designation is the first step in obtaining a Humanitarian Device Exemption (HDE) for the eTNS system. An approved HDE would allow NeuroSigma to market the eTNS system in the United States as an adjunctive treatment for the symptoms of LGS in children.

January 5, 2015
UCLA Launches Phase II Pediatric Clinical Trial for the Treatment of ADHD with NeuroSigma's eTNS System

NeuroSigma®, Inc. (NeuroSigma) today announced that enrollment has commenced for a 90-subject Phase II pediatric clinical trial of its external trigeminal nerve stimulation (eTNS) technology as treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). The trial is being conducted at the Semel Institute for Neuroscience and Human Behavior, located at the University of California, Los Angeles (UCLA).

November 19, 2014
NeuroSigma Congratulates Brazilian Medical Team for Their Top-Line Results in Phase II Clinical Trial of eTNS for Treatment of Depression

NeuroSigma®, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS system for the treatment of neurological and neuropsychiatric disorders, applauds the accomplishments of an independent team of Brazilian researchers led by Pedro Shiozawa, M.D., on their positive top-line findings from a Phase II clinical trial of eTNS as adjunctive treatment for major depressive disorder (MDD). The trial was conducted at the Santa Casa de Sao Paulo School of Medicine in Sao Paulo, Brazil.

November 17, 2014
NeuroSigma Announces Top-Line Findings of UCLA Phase II Clinical Trial of eTNS for the Treatment of Depression

NeuroSigma®, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS system for the treatment of neurological and neuropsychiatric disorders, announced today top-line findings from a Phase II dose-ranging study in major depressive disorder (MDD) conducted at the University of California, Los Angeles (UCLA). Funding for the trial was provided by NeuroSigma.

November 3, 2014
NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS)

NeuroSigma®, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS system for the treatment of neurological and neuropsychiatric disorders, announced today that the Mexican Institute of Industrial Property has issued a Notice of Allowance for Mexican Patent Application No. MX/a/2012/004051. The patent application is co-owned by NeuroSigma and the Regents of the University of California (Regents) as a result of research conducted by physicians and scientists at NeuroSigma and the University of California, Los Angeles (UCLA). NeuroSigma is the exclusive licensee of the Regents' rights to the patent application.

October 21, 2014
NeuroSigma Receives Notice of Allowance of U.S. Patent Application

NeuroSigma®, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS system for the treatment of neurological and neuropsychiatric disorders, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 12/898,685 entitled "Extracranial implantable devices, systems and methods for the treatment of neuropsychiatric disorders." The patent application is co-owned by NeuroSigma and the Regents of the University of California (Regents) as a result of research conducted by physicians and scientists at NeuroSigma and the University of California, Los Angeles (UCLA). NeuroSigma is the exclusive licensee of the Regents' rights to the patent application.

October 15, 2014
NeuroSigma and the U.S. Veterans Administration (VA) Enter into Cooperative Research and Development Agreement (CRADA)

NeuroSigma®, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS System for the treatment of neurological and neuropsychiatric disorders, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Veterans Affairs (VA) for a clinical trial to evaluate the benefits of non-invasive, external Trigeminal Nerve Stimulation (eTNS) for patients with traumatic brain injury (TBI) in a Phase I clinical trial.

August 26, 2014
NeuroSigma, Inc. Files Registration Statement for Proposed Initial Public Offering

NeuroSigma, Inc., a Los Angeles-based life sciences company established to develop bioelectronic technologies, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined.

August 25, 2014
U.S. Army Funds Phase II Clinical Trial at UCLA for the Treatment of PTSD with the NeuroSigma eTNS System

NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™ eTNS™ System for the treatment of neurological and neuropsychiatric disorders, today announced that the U.S. Department of the Army, through the U.S. Army Medical Research and Material Command, has funded a Phase II clinical trial at the University of California, Los Angeles (UCLA), that will examine the use of external trigeminal nerve stimulation (eTNS) as treatment for post-traumatic stress disorder (PTSD).

July 22, 2014
Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome

NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™ eTNS™ Therapy for the treatment of neurological and neuropsychiatric disorders, today announced that enrollment has begun in a pediatric open label study of external trigeminal nerve stimulation (eTNS) as adjunctive therapy for the treatment of Lennox-Gastaut Syndrome (LGS).

July 9, 2014
NIH Funds Phase 2 Clinical Trial at UCLA for the Treatment of ADHD with NeuroSigma's eTNS System

NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™ eTNS™ System for the treatment of neurological and neuropsychiatric disorders, today announced that the U.S. National Institutes of Health (NIH) has awarded UCLA a grant that funds a Phase II 90-subject pediatric clinical trial at the University of California, Los Angeles (UCLA) focused on the treatment of Attention Deficit Hyperactivity Disorder (ADHD) with NeuroSigma's external trigeminal nerve stimulation (eTNS) System.

July 8, 2014
Advances in Trigeminal Nerve Stimulation Featured at European Congress on Epileptology in Stockholm, Sweden

NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™ eTNS™ System for the treatment of neurological and neuropsychiatric disorders, today announced top-line summaries of presentations made last week at the 11th European Congress on Epileptology in Stockholm, Sweden, related to the use of external trigeminal nerve stimulation (eTNS) in epilepsy.

June 3, 2014
Leading UCLA Physician Dr. Ian Cook Joins NeuroSigma As Chief Medical Officer and Senior Vice President

NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™ eTNS™ System for the treatment of neurological and neuropsychiatric disorders, today announced that Ian A. Cook, M.D., has joined NeuroSigma on June 1, 2014 as Chief Medical Officer and Senior Vice President.

April 1, 2014
NeuroSigma Receives Approval from Australian Therapeutic Goods Administration to Market its Monarch™ eTNS™ System for the Adjunctive Treatment of Drug-Resistant Epilepsy

NeuroSigma, Inc., a California-based life-sciences company focused on commercialization of its non-invasive Monarch™ eTNS™ System for the treatment of neurological and neuropsychiatric disorders, today announced that it has received approval from the Therapeutic Goods Administration (TGA) to market its Monarch™ eTNS™ System in Australia. The approval allows NeuroSigma to market the Monarch eTNS System for the adjunctive treatment of drug-resistant epilepsy (DRE) in patients nine years of age and older.

March 28, 2014
NeuroSigma Expands Its Management Team with Two Former Amgen Finance Executives

NeuroSigma, Inc., a California-based life sciences company focused on commercialization of its non-invasive Monarch™ eTNS™ System for the treatment of neurological and neuropsychiatric disorders, announced the promotion of Carl Adams to Chief Financial Officer (CFO) and the appointment of Craig Rostamian as Vice President of Finance, overseeing Financial Planning & Analysis.

February 25, 2014
David Hayes, Former Partner at O'Melveny & Myers LLP and Haynes and Boone LLP, Joins NeuroSigma As Chief Administrative Officer, General Counsel and Sr. Vice President

NeuroSigma, Inc., a California-based life sciences company focused on commercialization of its non-invasive Monarch™ eTNS™ System for the treatment of neurological and neuropsychiatric disorders, announced the appointment of David Hayes, Esq. as Senior Vice President, Chief Administrative Officer, General Counsel and Corporate Secretary.

February 11, 2014
Former Amgen Finance Executive Carl Adams Joins NeuroSigma As Vice President and Controller

NeuroSigma, Inc., a California-based life sciences company focused on commercialization of its non-invasive Monarch™ eTNS™ System for the treatment of neurological and neuropsychiatric disorders, announced the appointment of Carl Adams as Vice President and Controller.

January 27, 2014
Former Allergan Marketing Executive Gregory F. Brooks Joins NeuroSigma As Senior VP and Chief Commercial Officer

NeuroSigma, Inc., a California-based life sciences company focused on commercialization of its non-invasive Monarch™ eTNS™ System for the treatment of neurologic and neuropsychiatric disorders, today announced the appointment of Gregory F. Brooks as Senior Vice President and Chief Commercial Officer.

January 21, 2014
External Trigeminal Nerve Stimulation (eTNS) Presentations at the American Epilepsy Society Meeting

NeuroSigma, Inc., a California-based life sciences company, today announced that two presentations were made last month at the annual American Epilepsy Society meeting held in Washington, DC, which reported positive results using external Trigeminal Nerve Stimulation (eTNS™) for the adjunctive treatment of epilepsy.

December 5, 2013
NeuroSigma Announces Receipt of Notice of Allowance of U.S. Patent Application Related to External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Epilepsy and other Neurological Disorders

NeuroSigma, Inc., a California-based life sciences company, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application. The claims of the application cover the use of trigeminal nerve stimulation (TNS) with cutaneous electrodes for the treatment of neurological disorders, including but not limited to epilepsy, migraine, and acute brain injury. "As an inventor, I am very pleased to see that over 10 years of research by our team is reaching fruition, and will now be covered by a US patent," said Christopher DeGiorgio, M.D., Vice President of Neurology at NeuroSigma, and Professor of Neurology at UCLA.

July 29, 2013
NeuroSigma Announces FDA Approval to Commence Phase III Trial

NeuroSigma, Inc., today announced conditional approval by the U.S. Food and Drug Administration (FDA) of its Investigational Device Exemption (IDE) application to commence a Phase III pivotal trial of the Monarch™ eTNS™ System for treatment of drug resistant epilepsy. The Company is planning to conduct a multi-center trial at leading medical institutions in the U.S., Europe and Canada. The objective of the study is to evaluate the safety and effectiveness of the device and provide the basis for a Pre‐Market Approval (PMA) application to the FDA.

June 21, 2013
NeuroSigma Announces Debut of Its Monarch eTNS System in Canada

NeuroSigma, Inc., a Los Angeles based medical device company, today announced that its Monarch™ eTNS™ System for the adjunctive treatment of epilepsy and depression will make its Canadian debut at the 30th International Epilepsy Congress, taking place in Montreal, Canada from June 23 to June 27, 2013. The Monarch eTNS System will be on display at the NeuroSigma Booth #413 throughout the conference.

June 6, 2013
NeuroSigma Launches Dedicated Website to Introduce Its Monarch eTNS System for Epilepsy and Depression

NeuroSigma, Inc., a California-based medical device company, today announced the launch of www.monarch-etns.com, its dedicated website for the Monarch eTNS System. The new site provides a comprehensive resource for those in the European Union and Canada who are considering use of the non-invasive Monarch system to treat their epilepsy and depression in conjunction with their existing drug treatment program. The therapeutic neuromodulation system is not yet approved for use in the United States.

May 20, 2013
Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS)

At the American Psychiatric Association (APA) Meeting in San Francisco, the results of a Phase I open-label pediatric clinical trial were presented. The study investigated the effects of external Trigeminal Nerve Stimulation (eTNS) on Attention Deficit Hyperactivity Disorder (ADHD) as stand-alone monotherapy (i.e., without use of medications of any kind). Mean improvements of over 40% were recorded after 4 weeks and over 45% after 8 weeks.

May 2, 2013
NeuroSigma Receives Health Canada Approval for Its Monarch eTNS System for the Treatment of Drug-Resistant Epilepsy and Major Depressive Disorder

NeuroSigma, Inc., a California-based medical device company, today announced that it has received a Class 2 medical device license for its Monarch eTNS (external trigeminal nerve stimulation) System from Health Canada. The license covers the use of the Monarch eTNS System for treatment of drug-resistant epilepsy (DRE), major depressive disorder (MDD), and treatment-resistant depression.

April 18, 2013
Results of Pediatric Clinical Trial of External Trigeminal Nerve Stimulation for the Treatment of ADHD

NeuroSigma, Inc., a California-based medical device company, today announced that the results of the first-ever pediatric clinical trial of external Trigeminal Nerve stimulation (eTNS) for the treatment of attention-deficit hyperactivity disorder (ADHD) will be presented at the American Psychiatric Association annual meeting in San Francisco on May 20, 2013.

March 25, 2013
External Trigeminal Nerve Stimulation (eTNS) For Refractory Status Epilepticus

NeuroSigma, Inc., a California-based medical device company, today announced that it will exhibit its CE Mark approved, non-invasive Monarch eTNS System for the adjunctive treatment of epilepsy and depression, at the 4th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures to be held in Salzburg, Austria from April 4-6, 2013. 

February 11th, 2013
NeuroSigma Invited to Present an Overview of eTNS for the Treatment of Epilepsy and Depression at The Royal Society of Medicine in London

NeuroSigma, Inc., a California-based medical device company, today announced that Christopher DeGiorgio , M.D., Vice President of Neurology at NeuroSigma and Professor of Neurology at the University of California, Los Angeles (UCLA), and Colin Kealey , M.D., Manager of Business Development at NeuroSigma, will present an overview of external trigeminal nerve stimulation (eTNS) for the treatment of epilepsy and depression at The Royal Society of Medicine's Sixth Medical Innovations Summit on February 16, 2013.

February 4th, 2013
NeuroSigma Awarded Fast Track SBIR Grant by the NIH for Development of Implantable sTNS System for Drug Resistant Epilepsy

NeuroSigma, Inc., a California-based medical device company, today announced it received a Notice of Award, for a Fast Track Small Business Innovation Research (SBIR) grant, from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH). Phase I of the project is budgeted in the amount of $600,000, with $3 Million budgeted for Phase II, subject to the availability of funds and satisfactory progress by NeuroSigma. 

January 30th, 2013
NeuroSigma Announces Publication of Randomized Controlled Trial of eTNS for Treatment of Drug Resistant Epilepsy in the Leading Journal, Neurology®

NeuroSigma, Inc., a California-based medical device company, today announced the publication of a positive Phase II clinical study for the use of external Trigeminal Nerve Stimulation (eTNS) for the treatment of drug-resistant epilepsy. The study, led by Christopher M. DeGiorgio , M.D., Professor of Neurology at the University of California, Los Angeles (UCLA) and Vice President of Neurology at NeuroSigma, was published online in the January 30, 2013 issue of Neurology®, the medical journal of the American Academy of Neurology.

January 22nd, 2013
NeuroSigma Announces Receipt of Notice of Allowance of U.S. Patent Application Related to External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Neuropsychiatric Disorders

NeuroSigma, Inc., a California -based medical device company, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 12/898,686 entitled "Devices, Systems and Methods For Treatment of Neuropsychiatric Disorders." The patent application, exclusively licensed to NeuroSigma, is owned by The Regents of the University of California (Regents) as a result of research conducted by physicians and scientists at the University of California, Los Angeles (UCLA).

September 25th, 2012
NeuroSigma's Monarch eTNS System to be Unveiled in London

NeuroSigma, Inc., a Los Angeles-based medical device company, announced today that its Monarch eTNS system for the adjunctive treatment of epilepsy and depression will make its debut at the 10th European Congress on Epileptology. "This conference represents an outstanding opportunity to put the Monarch in the hands of many healthcare professionals who will be future advocates of the system in the European Union.  Our team looks forward to forming alliances and introducing a new paradigm for the management of epilepsy," said Leon Ekchian, Ph.D., NeuroSigma's President & CEO.

September 5th, 2012
NeuroSigma Receives CE Certification

NeuroSigma, Inc., a Los Angeles-based medical device company, announced today that it received CE Certification for its external Trigeminal Nerve Stimulation (eTNS) system, called the Monarch, for the adjunctive treatment of epilepsy and major depressive disorder, for adults and children 9 years and older.  NeuroSigma's approval was supported by years of safety and compelling efficacy data generated in clinical trials conducted at the University of California, Los Angeles (UCLA) and the University of Southern California (USC).

July 2nd, 2012
NeuroSigma Receives Global Quality Control Certification

Today NeuroSigma, Inc., a Los Angeles-based medical device company, announced that it received ISO 13485: 2003 certification, indicating that it operates a Quality Management System for the design, manufacturing and distribution of its external Trigeminal Nerve Stimulation (eTNS) system for the treatment of neurological and neuropsychiatric disorders.  This certification is an important first step in a two-step process towards CE Mark approval in the European Union.

May 30th, 2012
Interim Results Reported for Phase I Open-Label Clinical Trial for the Treatment of PTSD and MDD Using External Trigeminal Nerve Stimulation (eTNS) - The USB Port to the Brain

Today, at the 52nd annual New Clinical Drug Evaluation Unit (NCDEU) Conference in Arizona, Ian Cook , M.D., Professor of Psychiatry at the University of California, Los Angeles (UCLA) and a Senior Medical Advisor to NeuroSigma, Inc., presented the results from the first 6-subject cohort of a 10-subject Phase I open-label clinical trial studying the effects of external trigeminal nerve stimulation (eTNS) on Post-Traumatic Stress Disorder (PTSD) and depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy.  The trial is being conducted at UCLA and is funded by NeuroSigma.  Mean decreases in PTSD measures of 36% and depression measures of over 50% were reported.

May 8th, 2012
Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS) - The USB Port to the Brain

Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook , Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy.    In the trial, subjects placed stimulating eTNS electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests.  eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.

April 2nd, 2012
UCLA Neurologist and Innovator of Trigeminal Nerve Stimulation Joins NeuroSigma

NeuroSigma, Inc., a Los Angeles-based medical device company, today announced its appointment of Christopher M. DeGiorgio , M.D., as Vice-President, Neurology. In this new role Dr. DeGiorgio, who was previously a Senior Medical Advisor to the Company, will lead NeuroSigma's development of Trigeminal Nerve Stimulation (TNS) for the treatment of neurological indications.  

November 29, 2011
NeuroSigma to Exhibit at the 2011 American Epilepsy Society Annual Meeting and Introduce External Trigeminal Nerve Stimulation - the USB Port to the Brain™

NeuroSigma, Inc., a Los Angeles-based medical technology company, today announced it will introduce its External Trigeminal Nerve Stimulation (eTNS™) system as an exhibitor at the 65th Annual American Epilepsy Society (AES) Meeting being held December 2-6, 2011 at the Baltimore Convention Center. NeuroSigma is the exclusive worldwide licensee of trigeminal nerve stimulation (TNS), which is a proprietary therapy originally developed at the University of California, Los Angeles (UCLA).  

October 24, 2011
NeuroSigma Funds First-Ever Pediatric Clinical Trial to Study Non-Invasive External Trigeminal Nerve Stimulation for the Treatment of ADHD

NeuroSigma, Inc., a Los Angeles-based medical technology company, announced today that it has signed a contract with the University of California, Los Angeles (UCLA) to fund a Phase I pediatric clinical trial to study the use of non-invasive, external Trigeminal Nerve Stimulation (TNS) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). NeuroSigma is the exclusive worldwide licensee of UCLA's TNS intellectual property.  

July 27, 2011
New Device Reduces Seizures, No Surgery Required

A experimental device that delivers electrical pulses to the forehead can help control epileptic seizures, say scientists at the University of California, Los Angeles. The device works by stimulating the trigeminal nerve, which runs just beneath the skin covering the eyebrows. Electrical signals follow that nerve to areas in the brain where seizures often begin, researchers say.  


To read more news about NeuroSigma and its product, visit our corporate website.

Back to Top